Dermata Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Details (Tables)

9 Months Ended

Sep. 30, 2023

	September 30,		December 31,
	2023		2022
Prepaid expenses and other current assets:
Prepaid insurance	$	586,359	$	586,407
Prepaid research and development costs		76,216		92,581
Prepaid other		29,249		11,604
Interest receivable		76		12,602
Total prepaid expenses and other current assets	$	691,900	$	703,194

Accrued and other current liabilities:
Accrued research and development costs	$	40,904	$	254,787
Accrued compensation and benefits		329,049		170,389
Accrued legal fees		72,402		-
Accrued other		4		756
Total accrued and other current liabilities	$	442,359	$	425,932